Financing & Policy

WHO Reports 2.6 Million TB Cases in Africa as Funding Gaps Persist

WHO estimates 2.61 million people developed TB in its African Region in 2025, while major funding gaps persist in Kenya, Nigeria and other high-burden countries.

A laboratory scientist examines samples as the WHO’s Global Tuberculosis Report 2026 highlights the burden of TB in Africa and the urgent need to close gaps in diagnosis, treatment and funding.
A laboratory scientist examines samples as the WHO’s Global Tuberculosis Report 2026 highlights the burden of TB in Africa and the urgent need to close gaps in diagnosis, treatment and funding.

The decision brief

What is changing?

WHO estimates 2.61 million people developed TB in the African Region in 2025, representing 25% of global cases. Incidence fell 30% and TB deaths 50% between 2015 and 2025, but 11 countries still had incidence rates above 300 per 100,000. The report identifies 2026 funding gaps of US$121 million in Kenya and US$85 million in Nigeria.

What is coming next?

Monitor national TB budget execution, rapid molecular testing coverage, treatment initiation for rifampicin-resistant TB, integration of TB/HIV services and the implementation of 2026 national strategic plans.

What does it mean?

Africa has reduced TB incidence faster than the global average since 2015, but it continues to carry one-quarter of global cases and a substantial share of TB/HIV mortality. Financing and diagnostic gaps threaten the pace and sustainability of progress.

What solutions are available?

Protect domestic TB budgets, coordinate external support, expand rapid molecular diagnosis, strengthen active case finding and contact investigation, integrate TB and HIV services, and improve access to shorter drug-resistant TB regimens.

Who is offering them?

WHO, national ministries of health and TB programmes, the Global Fund, African research institutions, diagnostic developers and civil-society organisations.

Nairobi, Kenya — An estimated 2.61 million people developed tuberculosis (TB) in the World Health Organization’s African Region in 2025, accounting for one-quarter of the global total, according to the WHO Global Tuberculosis Report 2026, released on 12 November. The report records progress in reducing the regional incidence rate, but warns that major gaps in diagnosis, treatment and financing continue to threaten efforts to end the disease.

The latest estimates put the African Region’s TB incidence rate at 201 cases per 100,000 people in 2025. The rate was 30% lower than in 2015, a stronger reduction than the global decline of 14%. However, the region still carried a substantial share of the worldwide burden, and the report identifies the need for faster progress in prevention, early diagnosis and treatment, particularly for people affected by HIV and drug-resistant TB.

Africa accounted for one in four new TB cases

WHO estimates that 2.61 million people fell ill with TB in its African Region in 2025, within a 95% uncertainty interval of 2.23 million to 3.02 million. An estimated 412,000 of these cases were among people living with HIV. The regional rate of 201 cases per 100,000 population was higher than the global estimate of 129 per 100,000. The regional average also masks substantial differences between countries: 11 countries in the WHO African Region had estimated incidence rates above 300 cases per 100,000 people in 2025.

The mortality burden remains severe. WHO estimates that 296,000 people without HIV died from TB in the African Region in 2025, alongside 99,000 deaths among people with HIV in which TB was a contributory cause. Under international mortality classification, deaths among people with HIV are recorded as HIV deaths rather than deaths caused by TB alone. The figures should therefore be read separately rather than treated as a single official TB-death category.

The report says the number of TB deaths in the African Region has fallen year on year since 2011. Between 2015 and 2025, the estimated total number of deaths from TB among people with and without HIV fell by 50% in the region, closer than any other WHO region to the End TB Strategy’s 75% reduction target for 2025. The decline is significant, but the continued scale of illness and mortality shows that gains depend on sustained case finding, treatment and prevention. WHO’s regional estimates are modelled estimates, not a count of all cases diagnosed by health facilities.

Diagnosis and drug-resistant TB remain major challenges

Across the world, an estimated 10.6 million people developed TB in 2025, but only 8.4 million were diagnosed and reported to WHO. The remaining 2.2 million were either undiagnosed or not reported. WHO also found that 59% of newly diagnosed patients received a WHO-recommended rapid diagnostic test as their initial test, below the 100% target set for 2027. In the WHO African Region, bacteriological confirmation of pulmonary TB improved from 65% to 71% between 2020 and 2025.

Drug-resistant TB remains a further concern. WHO recorded 155,333 people enrolled on treatment for rifampicin-resistant TB worldwide in 2025, 5.8% fewer than in 2024; the number remained far below the estimated incidence of drug-resistant disease. Among people treated for rifampicin-resistant TB, use of six-month regimens increased from 18% in 2024 to 42% in 2025. These are global figures; the report’s country and regional data should be used when assessing individual African programmes.

For African health systems, the findings reinforce the need to expand access to rapid molecular testing, strengthen laboratory networks, improve referral from community screening to treatment, and ensure that people diagnosed with drug-resistant disease can start and complete appropriate regimens. TB and HIV services also need to remain closely integrated, given the substantial number of regional cases among people living with HIV.

Funding gaps put national plans under pressure

The report highlights a difficult financing environment. Across low- and middle-income countries, total funding for TB prevention, diagnosis and treatment reached US$6.6 billion in 2025. Domestic sources accounted for 86% of this amount, while international donor funding fell by 14%, from US$1.1 billion in 2024 to US$940 million in 2025.

The headline share of domestic financing masks significant concentration. Five original BRICS countries — Brazil, Russia, India, China and South Africa — accounted for about 65% of the US$5.6 billion in domestic funding reported for 2025. WHO says international funding remains critical in many other high-burden and low-income countries.

For 2026, 54 low- and middle-income countries reported that available funding was insufficient to implement their national TB strategic plans, with a combined reported gap of US$1.7 billion. WHO said the largest gaps were reported by countries in the African and Western Pacific regions. Among high-burden countries, Kenya reported a US$121 million gap and Nigeria US$85 million. These figures describe the difference between planned requirements and expected funding; they are not evidence that the entire amount has been formally withdrawn or that every programme has already stopped services.

Research and innovation need predictable investment

WHO estimates that global TB research funding stood at US$1.2 billion in 2023, less than one-quarter of the US$5 billion annual target set for 2027. The shortfall affects the development and evaluation of new vaccines, diagnostics and treatments, as well as the evidence needed to introduce innovations fairly across high-burden settings.

In a 12 November response to the report, Wellcome’s Head of Vaccines said that promising TB vaccine and treatment candidates are moving through late-stage trials, but stressed that equitable access and financing arrangements will be needed if new interventions are to reach countries with the greatest burden.

New tools can support progress only if countries can procure them, train health workers, maintain laboratory equipment and connect test results to treatment. Near-point-of-care molecular tests and shorter drug-resistant TB regimens may help address longstanding barriers, but their value depends on affordability, quality assurance, supply continuity and access outside major urban centres. Health Signal Africa has previously covered infectious-disease research priorities in sub-Saharan Africa and evidence on computer-aided TB detection in Ghana.

What African programmes need to prioritise

The report’s findings point to practical priorities for ministries of health and national TB programmes: protect domestic budget allocations; identify funding gaps early; expand rapid molecular diagnosis; strengthen active case finding and contact investigation; integrate TB and HIV services; and improve access to treatment for rifampicin-resistant disease. Community organisations and people affected by TB also need to be involved in designing services that reduce stigma, transport costs and delays in care.

For Kenya and Nigeria, the reported 2026 funding gaps provide a warning for budget planning and partner coordination. Governments and funders will need to show how planned resources translate into tests, medicines, trained staff and uninterrupted treatment. Progress should be assessed using transparent national data on diagnosis, treatment initiation, completion and patient costs.

WHO’s report shows that the African Region has made measurable progress over the past decade, but that progress remains vulnerable. Reducing new infections further will require not only better diagnostics and treatment regimens, but also predictable financing and health services that can reach people before they become seriously ill.

Sources and limitations

This article is based on the WHO Global Tuberculosis Report 2026, the report’s regional incidence estimates, mortality estimates and TB financing analysis, published on 12 November 2026. WHO’s African Region is a defined group of 47 Member States and should not be read as identical to the entire African continent. Incidence and mortality figures are estimates with uncertainty intervals. Deaths among people with HIV are classified as HIV deaths, with TB recorded as a contributory cause. National funding gaps are reported planning shortfalls, not confirmed service interruptions.

Discussion

Leave a Reply

Your email address will not be published. Required fields are marked *